sapro [bicalutamid actavis]
sanoswiss, uab - bikalutamidas - plėvele dengtos tabletės - 50 mg - bicalutamide
sapro [bicalutamid actavis]
sanoswiss, uab - bikalutamidas - plėvele dengtos tabletės - 150 mg - bicalutamide
bicalutamide accord
accord healthcare b.v. - bikalutamidas - plėvele dengtos tabletės - 50 mg - bicalutamide
bicalutamide grindeks
as grindeks - bikalutamidas - plėvele dengtos tabletės - 50 mg - bicalutamide
bicalutamide kabi
fresenius kabi polska sp.z.o.o. - bikalutamidas - plėvele dengtos tabletės - 50 mg - bicalutamide
bicalutamide-teva
teva pharma b.v. - bikalutamidas - plėvele dengtos tabletės - 150 mg - bicalutamide
calumid
gedeon richter plc - bikalutamidas - plėvele dengtos tabletės - 150 mg; 50 mg - bicalutamide
casodex
astrazeneca ab - bikalutamidas - plėvele dengtos tabletės - 150 mg - bicalutamide
bicalutamide accord
accord healthcare b.v. - bikalutamidas - plėvele dengtos tabletės - 150 mg - bicalutamide
xtandi
astellas pharma europe b.v. - enzalutamidas - prostatos navikai - endokrininė terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.